Jangdeok Nokyong Research Institute - Iworld Pharmaceutical Affiliated Research Institute Sign Technology Agreement for Joint Development of Health Foods
Jangdeok Nokyong Research Institute announced on the 29th that it has signed a technology patent sharing agreement with IWorld Pharmaceutical's affiliated research institute, a company specializing in the development of natural herbal medicine-based pharmaceuticals, to jointly develop health foods.
I-World Pharmaceutical Research Institute and Jangdeok Nokyong Research Institute signed a technology patent sharing agreement on the 29th for the joint development of health supplements.
[Photo by Jangdeok Nokyong Research Institute]
Through this agreement, both companies have agreed to combine their efforts to develop new drugs, health functional improvement foods, general health processed foods, and other specialized products based on the technology patents for natural herbal substance extraction held by each company.
The technology patents that IWorld Pharmaceutical's affiliated research institute will share with Jangdeok Nokyong Research Institute total six types. These include three patents for herbal extracts that promote growth hormone secretion, two patents for fermented kudzu root extracts that help prevent osteoporosis, obesity, or hyperlipidemia, and other composition patents that aid in the prevention of thrombotic diseases.
Jangdeok Nokyong Research Institute is a health food company established by Shin Gwangsoon, director of Jangdeok Korean Medicine Hospital, well known for immune cancer treatment and frozen shoulder therapy, along with ten Korean medicine doctors affiliated with the hospital. Based on the accumulated clinical experience and herbal prescription know-how of the Korean medicine doctors, the company has attracted attention by consecutively launching liquid pouches and agarwood pills using Russian deer antler as the main ingredient.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Less Than a Year Later... Eunma Apartment Reconstruction Payments Surge by 300 Million Won
- "Manhole Cover Blasts Open in 12 Seconds... The Reason Behind the 'Gangnam Flood Disaster' [Report]"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Jeon Gwangseok, CEO of IWorld Pharmaceutical's affiliated research institute, said, "It is meaningful that our company's growth hormone secretion extract and osteoporosis prevention extract can be upgraded to a new level through collaboration with a health food company established by a prestigious Korean medicine hospital." Shin Gyeongae, CEO of Jangdeok Nokyong Research Institute, expressed expectations, saying, "Through this patent technology sharing agreement, we will be able to develop high value-added new products."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.